Clinical use of amphotericin B in patients with malignant hematological diseases combined with invasive fungal disease
LIANG Wen-xin1,4, ZHOU Wei-ying1,2, LI Fei3, XU Juan4, BAI Nan4, CAI Yun4, WANG Ting-ting1,2
1. Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; 2. Chongqing Key Laboratory of Drug Metabolism Research, Chongqing 400016, China; 3. Department of Hematology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China; 4. Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center, Chinese PLA General Hospital, Beijing 100853, China
Abstract：Objective To analyze the clinical use of amphotericin B in hospitalized patients with malignant hematological diseases combined with invasive fungal disease (IFD) in Chinese PLA General Hospital, and provide basis for guiding rational clinical use of drugs.Methods From January to December 2021, hospitalized patients with malignant hematological diseases complicated with IFD and treated with amphotericin B in the Hematology Department and Hematopoietic Stem Cell Transplantation Ward of Chinese PLA General Hospital were selected as studied objects, and their demographic characteristics, imaging examination, fungal laboratory examination, usage and dosage of amphotericin B were analyzed.Results A total of 131 patients were enrolled, 26 cases (19.85%)were clinically diagnosed IFD, 52 cases (39.69%)were suspected, and 53 cases (40.46%)were undetermined. 28.57% (34/119) patients had positive (1,3)-beta-D-glucan assay, 13.45% (16/119) had positive Galactomannan test, and 44.64% (50/112) had positive fungal culture. A total of 64 strains of fungi were cultured, most were Candida spp. (n=55) Usage and dosage of amphotericin B: 111 cases (84.73%) were treated with amphotericin B deoxycholate (d-AmB), 61 (46.56%) were treated by intravenous drip, 13 (9.92%) were treated with 0.9% sodium chloride injection as solvent, and 55 (41.98%) were treated with dexamethasone sodium phosphate before treatment. 109 patients (83.21%) were treated with antifungal combination regimen, most were d-AmB combined with voriconazole. The drug utilization index (DUI) value of d-AmB for intravenous drip and atomization inhalation were both<1.00, and the DUI value of amphotericin B liposome (L-AmB) for intravenous drip was 1.04.Conclusion Amphotericin B is rationally used in this hospital, and the choice of solvent needs to be improved in order to obtain higher clinical benefits.
梁文馨, 周维英, 李菲, 徐娟, 白楠, 蔡芸, 王婷婷. 两性霉素B在恶性血液病合并侵袭性真菌病患者中的临床应用[J]. 中国感染控制杂志, 2022, 21(11): 1068-1074.
LIANG Wen-xin, ZHOU Wei-ying, LI Fei, XU Juan, BAI Nan, CAI Yun, WANG Ting-ting. Clinical use of amphotericin B in patients with malignant hematological diseases combined with invasive fungal disease. Chinese Journal of Infection Control, 2022, 21(11): 1068-1074.
Sanguinetti M, Posteraro B, Beigelman-Aubry C, et al. Diagnosis and treatment of invasive fungal infections:looking ahead[J]. J Antimicrob Chemother, 2019, 74(Suppl 2):ii27-ii37.
[2]
Sun YQ, Meng FY, Han MZ, et al. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China:a multicenter prospective observational study[J]. Biol Blood Marrow Transplant, 2015, 21(6):1117-1126.
[3]
Chen XC, Wang JX, Wang SB, et al. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients:a retrospective observational study[J]. Medicine (Baltimore), 2021, 100(30):e26772.
[4]
中国医师协会血液科医师分会, 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第六次修订版)[J]. 中华内科杂志, 2020, 59(10):754-763. Chinese Association Hematologists, Chinese Invasive Fungal Infection Working Group. The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision)[J]. Chinese Journal of Internal Medicine, 2020, 59(10):754-763.
[5]
Nett JE, Andes DR. Antifungal agents:spectrum of activity, pharmacology, and clinical indications[J]. Infect Dis Clin North Am, 2016, 30(1):51-83.
[6]
曹季平. 基于《社区获得性肺炎诊断和治疗指南(2016版)》对医院成人CAP患者抗菌药物使用的相关因素分析[J]. 抗感染药学, 2020, 17(3):323-327. Cao JP. Analysis of relevant factor of antibiotic medication in adult patients with CAP in hospital based on "Guidelines of CAP 2016 Edition"[J]. Anti-Infection Pharmacy, 2020, 17(3):323-327.
[7]
钱柯羽, 吕全省, 戴丽君, 等. G及GM试验在急性白血病合并侵袭性真菌病中的诊断价值[J]. 中国实验血液学杂志, 2019, 27(5):1678-1681. Qian KY, Lv QS, Dai LJ, et al. Diagnostic value of G and GM tests in acute leukemia patients with invasive fungal di-sease[J]. Journal of Experimental Hematology, 2019, 27(5):1678-1681.
[8]
李航, 方文捷, 熊林, 等. 侵袭性真菌感染早期诊断技术的研究进展[J]. 菌物学报, 2019, 38(2):151-158. Li H, Fang WJ, Xiong L, et al. Research progress on early diagnosis of invasive fungal infection[J]. Mycosystema, 2019, 38(2):151-158.
[9]
Alexander BD, Lamoth F, Heussel CP, et al. Guidance on imaging for invasive pulmonary aspergillosis and mucormycosis:From the imaging working group for the revision and update of the consensus definitions of fungal disease from the EORTC/MSGERC[J]. Clin Infect Dis, 2021, 72(Suppl 2):S79-S88.
[10]
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium[J]. Clin Infect Dis, 2020, 71(6):1367-1376.
[11]
《抗菌药物临床应用指导原则》修订工作组. 抗菌药物临床应用指导原则(2015年版)[M]. 北京:人民卫生出版社, 2015. The revised working group from clinical application of antibacterial drugs guiding principles. Clinical application of antibacterial drugs guiding priciple (2015)[M]. Beijing:People's Medical Publishing House, 2015.
[12]
Qiu KY, Liao XY, Fang JP, et al. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders[J]. Transpl Infect Dis, 2019, 21(3):e13066.
[13]
Vikelouda K, Simitsopoulou M, Skoura L, et al. Activity of amphotericin B formulations and voriconazole, alone or in combination, against biofilms of Scedosporium and Fusarium spp[J]. Antimicrob Agents Chemother, 2021, 65(11):e0063821.
[14]
Hamill RJ. Amphotericin B formulations:a comparative review of efficacy and toxicity[J]. Drugs, 2013, 73(9):919-934.
[15]
Steimbach LM, Tonin FS, Virtuoso S, et al. Efficacy and safety of amphotericin B lipid-based formulations-a systematic review and Meta-analysis[J]. Mycoses, 2017, 60(3):146-154.
[16]
Paterson DL, David K, Mrsic M, et al. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC:data from the patient registry of amphotericin B cholesteryl sulfate complex for injection clinical tolerability (PRoACT) registry[J]. J Antimicrob Chemother, 2008, 62(6):1392-1400.
Xia D, Sun WK, Tan MM, et al. Aerosolized amphotericin B as prophylaxis for invasive pulmonary aspergillosis:a Meta-analysis[J]. Int J Infect Dis, 2015, 30:78-84.
[19]
Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients[J]. Cochrane Database Syst Rev, 2014, 2014(9):CD000239.
[20]
Wittekamp BH, Ong DSY, Cremer OL, et al. Nystatin versus amphotericin B to prevent and eradicate Candida colonization during selective digestive tract decontamination in critically ill patients[J]. Intensive Care Med, 2015, 41(12):2235-2236.
[21]
Kaur K, Kumar P, Kush P. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection[J]. Biomed Pharmacother, 2020, 128:110297.
[22]
Liu M, Chen MW, Yang ZW. Design of amphotericin B oral formulation for antifungal therapy[J]. Drug Deliv, 2017, 24(1):1-9.
[23]
刘荣, 路霞林, 董平. 注射用两性霉素B与不同厂家5%葡萄糖注射液的配伍稳定性考察[J]. 中国药房, 2015, 26(20):2771-2773. Liu R, Lu XL, Dong P. Study on the compatible stability of amphotericin B for injection and 5% glucose injection from different manufacturers[J]. China Pharmacy, 2015, 26(20):2771-2773.
